ATS Corporation (TSX/NYSE: ATS) reported fiscal Q2 2027 results on November 4, 2026 that left little room for comfort on the surface. Revenue fell 8.6% year over year to C$665.8 million. Adjusted EBITDA dropped to C$80.7 million from C$103.7 million. The company withdrew its full-year guidance for modest revenue growth and margin expansion. The stock dropped roughly 7% on the day.

That reaction is understandable. What it misses is the asset underneath the miss.

The Backlog Divergence

Even as revenue compressed, ATS reported order bookings of C$827 million in Q2, up 12.7% from a year earlier. Total order backlog reached C$2,009 million. Life sciences backlog alone hit C$1.238 billion, described by management as the highest in the company’s history. Energy backlog sits at C$236 million, underpinned by nuclear refurbishment and life-extension contracts for CANDU reactors, alongside front-end engineering work for small modular reactors.

That combination, regulated-market automation at scale, positions ATS differently than its near-term financials suggest. Management has identified nuclear and radiopharmaceuticals as explicit reinvestment targets within its fixed-cost transformation. The 15-month restructuring program is expected to pay back in under a year, with the long-term adjusted earnings from operations margin target holding at 15%, against the current 8.6%.

The Buyout Math

ATS has lost 31.4% year to date, with shares near US$18.92 against a 52-week high of US$35.82. The average analyst price target sits at C$37.05, implying roughly 51% upside from the last close of C$24.59. The stock trades at approximately 0.84x trailing sales on a business that generated C$2.97 billion in fiscal 2026 revenue, up 11% year over year, with a 15.7% five-year adjusted revenue CAGR.

That valuation compression is arriving precisely as the M&A environment for industrial automation reaches a cyclical peak. Industrial manufacturing deal values hit a record US$173 billion over the past year, a 28% jump from the prior year, according to PwC’s 2026 midyear outlook. Strategic acquirers account for 69.6% of automation deal volume year to date in 2026, with 92 announced or completed transactions against a five-year average of 84. Reshoring and onshoring of manufacturing capacity remain explicit deal drivers, with buyers paying premium multiples for companies at critical control points in sensing, controls, and domain-specific industrial automation.

Reshoring is not just a deal rationale — it is now a measurable capex cycle. U.S. manufacturing construction spending has risen 148% since the pre-CHIPS Act baseline, turning policy aspiration into earnings-relevant capital flows.

ATS sits squarely in that profile. It operates more than 65 manufacturing facilities across North America, Europe, Asia, and Oceania, employs over 7,000 people, and holds regulated-market automation capabilities spanning pharmaceuticals, nuclear, and food and beverage. Its trailing book-to-bill ratio is 1.05x. Cash flows from operating activities in Q2 were not disclosed as a standalone quarterly figure in the Q2 filing, but cash flows provided by operating activities were C$70.3 million for the first six months of FY2027, versus C$184.3 million in the same period a year ago.

Scenario Framework

Bull case: The fixed-cost transformation delivers its sub-one-year payback, margins recover toward 10% by Q4 FY2027, and life sciences backlog converts at an accelerating pace. A strategic acquirer, a large industrial conglomerate with reshoring exposure, moves on the depressed valuation. At 11x forward EBITDA, a reasonable automation sector multiple, the enterprise value would be materially above current market cap.

Base case: Revenue stabilizes in the C$700 million range per quarter as backlog converts, margins recover partially toward 10% by mid-FY2027, and the stock rerates modestly toward C$30. No acquisition occurs, but the buyback program, which repurchased about 2.24 million shares for C$61.3 million in Q2 alone, continues to tighten the float.

Bear case: Bookings soften in life sciences after the record quarter proves a timing anomaly. The 8.6% margin proves sticky rather than transitional. Guidance withdrawal signals broader execution risk, and the stock retests the 52-week low of US$17.15.

Trading Framework

ATS is trading below its 200-day moving average and near the lower bound of its 50-day range of US$17.30 to US$19.82. The VWAP on the TSX on the most recent active session was approximately C$26.69, with the stock closing below that level. Volume has been running near average, suggesting institutional distribution has not accelerated, but accumulation has not materialized either.

Key levels to monitor: a close above US$20 on the NYSE listing would signal the Q2 reaction is absorbed. A failure to hold US$17.15 reopens downside into uncharted territory. The next earnings catalyst is Q3 FY2027, expected in early February 2027, where any margin recovery evidence will be the fulcrum for repositioning.

Disciplined traders watch the backlog-to-revenue conversion rate, the restructuring cost trajectory, and whether Q3 bookings sustain above the C$800 million level that now defines the bull case. Preparation, not prediction, is the edge here.